5-11岁儿童接种辉瑞-BioNTech COVID-19疫苗加强针的安全性监测——美国,2022年5月17日至7月31日
美国CDC分析了2022年5月17日至7月31日5-11岁儿童接种辉瑞-BioNTech第三剂后的安全性监测数据。v-safe报告局部和全身反应在第二剂和第三剂后频率相似,部分反应在第三剂后更常为中度或重度。VAERS收到581份不良事件报告,其中578份(99.5%)为非严重事件,3份(0.5%)为严重事件,无心肌炎或死亡报告。
要点
- 约657,302名5-11岁美国儿童接种了辉瑞-BioNTech第三剂,v-safe报告3,249剂次。
- v-safe显示第三剂后局部和全身反应频率与第二剂相似,部分反应更常为中度或重度。
- VAERS收到581份报告,578份(99.5%)为非严重事件,3份(0.5%)为严重事件,无心肌炎或死亡报告。
核心结论
- 5-11岁儿童接种辉瑞-BioNTech第三剂后局部和全身反应常见,但严重不良事件报告罕见。
- 初步安全性发现与临床试验结果一致。
研究设计与样本
- CDC审查了2022年5月17日至7月31日期间5-11岁儿童接种辉瑞-BioNTech第三剂后向v-safe和VAERS报告的不良事件和健康影响评估。
- v-safe是基于智能手机的自愿性安全性监测系统,VAERS是由CDC和FDA共同管理的被动疫苗安全性监测系统。
- 期间约657,302名5-11岁美国儿童接种了第三剂辉瑞-BioNTech疫苗,v-safe报告了3,249剂次。
主要发现
- v-safe报告显示,第二剂和第三剂后局部和全身反应频率相似,部分反应(如疼痛)在第三剂后更常报告为中度或重度。
- VAERS收到581份5-11岁儿童接种辉瑞-BioNTech第三剂后的不良事件报告,其中578份(99.5%)被认为非严重,最常见的报告事件为疫苗接种操作错误。
- 3份(0.5%)报告被认为严重,未收到心肌炎或死亡报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On May 17, 2022, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine to authorize a homologous* booster dose for children aged 5-11 years ≥5 months after receipt of the second primary series dose† (1) based on findings from a clinical trial conducted among 401 children aged 5-11 years (2). To further characterize the safety of booster vaccination in this age group, CDC reviewed adverse events and health impact assessments after receipt of a Pfizer-BioNTech third dose reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events occurring after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system comanaged by CDC and FDA. During May 17-July 31, 2022, approximately 657,302 U.S. children aged 5-11 years received a third Pfizer-BioNTech dose (either a third primary series dose administered to immunocompromised children or a booster dose administered to immunocompetent children)§; 3,249 Pfizer-BioNTech third doses were reported to v-safe for children in this age group. Local and systemic reactions were reported to v-safe after a second dose and a third dose with similar frequency; some reactions (e.g., pain) were reported to be moderate or severe more frequently after a third dose. VAERS received 581 reports of adverse events after receipt of a Pfizer-BioNTech third dose by children aged 5-11 years; 578 (99.5%) reports were considered nonserious, and the most common events reported were vaccine administration errors. Three (0.5%) reports were considered serious; no reports of myocarditis or death were received. Local and systemic reactions were common among children after Pfizer-BioNTech third dose vaccination, but reports of serious adverse events were rare. Initial safety findings are consistent with those of the clinical trial (2).
引用
- Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35980875. doi:10.15585/mmwr.mm7133a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。